Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

NCT02763319 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02763319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02763319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
Lead sponsor
Incyte Corporation
Phase
Phase 2/3
Overall status
Completed
Start date
November 28, 2016
Completion date
June 21, 2024
Enrollment
453 (actual)
Sites
158

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma